Results 11 to 20 of about 2,825 (179)
Bioresorbable Vascular Scaffolds
JACC: Cardiovascular Interventions, 2016 In recent years, bioresorbable vascular scaffolds (BVS) have been introduced into clinical practice. The main advantage of BVS is that they overcome the problem of the foreign body in the treated artery. BVS, once placed into narrowed coronary vessels, behave like a conventional drug-eluting stent, but a device that disappears over time can preserve ...
Devito, Fiorella +10 more
openaire +4 more sources
Bioresorbable Vascular Scaffolds
JACC: Cardiovascular Interventions, 2018 In this chapter, current limitations of existing metallic drug-eluting stent technology and potential advantages of bioresorbable scaffolds (BRSs) are explored, alongside existing clinical data for BRSs and interventional techniques that may optimize implantation of these novel first-generation devices, with consequent potential for improved clinical ...
Ehtisham Mahmud, Ryan R. Reeves
openaire +2 more sources
Bioresorbable Polymeric Vascular Scaffolds [PDF]
Circulation: Cardiovascular Interventions, 2011 The everolimus-eluting bioresorbable vascular scaffold (BVS, Abbott Vascular, Santa Clara, CA) is an exciting advance in percutaneous coronary intervention (PCI), providing a temporary coronary scaffold for at least 3 months and being resorbed by about 2 years.1–3 Along with patient preference, potential advantages over metallic stents include restored
Ormiston, JA +3 more
openaire +3 more sources
Advances in Interventional Cardiology, 2020 The largest amount of evidence for bioresorbable vascular scaffold (BVS) use in clinical practice derives from Absorb trials and registries. Comparison of Absorb BVS with metallic stents resulted in increased rates of target lesion failure and device ...
Beytullah Cakal +8 more
doaj +1 more source
International Journal of Cardiology: Heart & Vasculature, 2020 Aims: The ABSORB bioresorbable vascular scaffold raised safety concerns due to higher rates of scaffold thrombosis (ScT) and adequate scaffold diameter and length for scaffold technology.
Myron Zaczkiewicz +8 more
doaj +1 more source
Bioresorbable Vascular Scaffolds for Coronary Revascularization [PDF]
Circulation, 2016 Contemporary metallic drug-eluting stents are associated with very good 1-year outcomes but an ongoing risk of stent-related adverse events (thrombosis, myocardial infarction, restenosis) after 1 year. The pathogenesis of these very late events is likely related to the permanent presence of the metal stent frame or polymer. Bioresorbable scaffolds have
Kereiakes, DJ +3 more
openaire +3 more sources
Bioresorbable vascular scaffolds—time to vanish? [PDF]
Journal of Thoracic Disease, 2016 The fully bioabsorbable vascular scaffold (BVS) has been developed to reduce late adverse events after coronary stenting such as device thrombosis. The device consists of polylactic acid, which is gradually absorbed within the first few years after its implantation.
Diego, Arroyo +2 more
openaire +2 more sources
Bioactive Materials, 2022 Bioresorbable scaffolds have emerged as a new generation of vascular implants for the treatment of atherosclerosis, and designed to provide a temporary scaffold that is subsequently absorbed by blood vessels over time.
Tieying Yin +12 more
doaj +1 more source
Advances in Interventional Cardiology, 2016 Introduction: There are limited data on the comparison of bioresorbable vascular scaffold (BVS) and drug-eluting stent (DES)/bare-metal stent (BMS) implantation in an unselected population of patients with coronary artery disease.
Łukasz Rzeszutko +5 more
doaj +1 more source
Bioresorbable Scaffolds: Contemporary Status and Future Directions
Frontiers in Cardiovascular Medicine, 2020 Percutaneous coronary intervention, which is safe, effective, and timely, has become an important treatment for coronary artery diseases and has been widely used in clinical practice. However, there are still some problems that urgently need to be solved.
Xiang Peng +12 more
doaj +1 more source